John G Kelton

Summary

Affiliation: McMaster University
Country: Canada

Publications

  1. doi request reprint Predictors of clinical outcome in patients with heparin-induced thrombocytopenia treated with direct thrombin inhibition
    John G Kelton
    Department of Medicine, McMaster University, Hamilton, Ontario, Canada
    Blood Coagul Fibrinolysis 19:471-5. 2008
  2. doi request reprint Heparin-induced thrombocytopenia: a historical perspective
    John G Kelton
    Michael G DeGroote School of Medicine, McMaster University, Hamilton, ON, Canada
    Blood 112:2607-16. 2008
  3. ncbi request reprint The pathophysiology of heparin-induced thrombocytopenia: biological basis for treatment
    John G Kelton
    McMaster University, 1200 Main St West, Room 2E1, Hamilton, ON, L8N 3Z5, Canada
    Chest 127:9S-20S. 2005
  4. pmc Approach to the diagnosis and management of drug-induced immune thrombocytopenia
    Donald M Arnold
    Michael G DeGroote School of Medicine, Department of Medicine, McMaster University, Hamilton, Ontario, Canada
    Transfus Med Rev 27:137-45. 2013
  5. pmc Sustained remissions of immune thrombocytopenia associated with the use of thrombopoietin receptor agonists
    Bahareh Ghadaki
    Department of Medicine, Michael G DeGroote School of Medicine, McMaster University, Hamilton, Ontario, Canada Department of Medicine and Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario, Canada Department of Medicine, McMaster University, Hamilton, Ontario, Canada Canadian Blood Services, Hamilton, Ontario, Canada
    Transfusion 53:2807-12. 2013
  6. doi request reprint A pilot randomized trial of adjuvant rituximab or placebo for nonsplenectomized patients with immune thrombocytopenia
    Donald M Arnold
    Department of Medicine, Michael G DeGroote School of Medicine, McMaster University, Hamilton, Ontario, Canada
    Blood 119:1356-62. 2012
  7. doi request reprint Studies of the immune response in heparin-induced thrombocytopenia
    Theodore E Warkentin
    Department of Pathology and Molecular Medicine, Michael G DeGroote School of Medicine, McMaster University, Hamilton, ON, Canada
    Blood 113:4963-9. 2009
  8. ncbi request reprint Current options for the treatment of idiopathic thrombocytopenic purpura
    Donald M Arnold
    Department of Medicine, Michael G DeGroote School of Medicine, McMaster University, Hamilton, Ontario, Canada
    Semin Hematol 44:S12-23. 2007
  9. doi request reprint Combination immunosuppressant therapy for patients with chronic refractory immune thrombocytopenic purpura
    Donald M Arnold
    Department of Medicine, Michael G DeGroote School of Medicine, McMaster University, Hamilton, ON, Canada
    Blood 115:29-31. 2010
  10. pmc Anti-platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin
    Theodore E Warkentin
    Department of Pathology and Molecular Medicine, McMaster University, Hamilton, ON, Canada
    Blood 106:3791-6. 2005

Detail Information

Publications39

  1. doi request reprint Predictors of clinical outcome in patients with heparin-induced thrombocytopenia treated with direct thrombin inhibition
    John G Kelton
    Department of Medicine, McMaster University, Hamilton, Ontario, Canada
    Blood Coagul Fibrinolysis 19:471-5. 2008
    ..The identification of higher risk subgroups for poor outcomes, such as patients with more severe thrombocytopenia or a history of renal impairment or peripheral vascular surgery, could allow more targeted therapy...
  2. doi request reprint Heparin-induced thrombocytopenia: a historical perspective
    John G Kelton
    Michael G DeGroote School of Medicine, McMaster University, Hamilton, ON, Canada
    Blood 112:2607-16. 2008
  3. ncbi request reprint The pathophysiology of heparin-induced thrombocytopenia: biological basis for treatment
    John G Kelton
    McMaster University, 1200 Main St West, Room 2E1, Hamilton, ON, L8N 3Z5, Canada
    Chest 127:9S-20S. 2005
  4. pmc Approach to the diagnosis and management of drug-induced immune thrombocytopenia
    Donald M Arnold
    Michael G DeGroote School of Medicine, Department of Medicine, McMaster University, Hamilton, Ontario, Canada
    Transfus Med Rev 27:137-45. 2013
    ..Improved standardization and accessibility of laboratory testing should be a focus of future research. ..
  5. pmc Sustained remissions of immune thrombocytopenia associated with the use of thrombopoietin receptor agonists
    Bahareh Ghadaki
    Department of Medicine, Michael G DeGroote School of Medicine, McMaster University, Hamilton, Ontario, Canada Department of Medicine and Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario, Canada Department of Medicine, McMaster University, Hamilton, Ontario, Canada Canadian Blood Services, Hamilton, Ontario, Canada
    Transfusion 53:2807-12. 2013
    ..Thrombopoietin receptor agonists (TRAs) are effective treatments for immune thrombocytopenia (ITP). However, continuous therapy is generally required to maintain platelet (PLT) count responses...
  6. doi request reprint A pilot randomized trial of adjuvant rituximab or placebo for nonsplenectomized patients with immune thrombocytopenia
    Donald M Arnold
    Department of Medicine, Michael G DeGroote School of Medicine, McMaster University, Hamilton, Ontario, Canada
    Blood 119:1356-62. 2012
    ..No difference in the frequency of the composite outcome was observed in this pilot trial (registered at www.clinicaltrials.gov NCT00372892)...
  7. doi request reprint Studies of the immune response in heparin-induced thrombocytopenia
    Theodore E Warkentin
    Department of Pathology and Molecular Medicine, Michael G DeGroote School of Medicine, McMaster University, Hamilton, ON, Canada
    Blood 113:4963-9. 2009
    ..Compared with seropositive non-HIT controls, HIT patients develop significantly higher anti-PF4/heparin IgG levels that are detectable before the onset of thrombocytopenia...
  8. ncbi request reprint Current options for the treatment of idiopathic thrombocytopenic purpura
    Donald M Arnold
    Department of Medicine, Michael G DeGroote School of Medicine, McMaster University, Hamilton, Ontario, Canada
    Semin Hematol 44:S12-23. 2007
    ..A move towards early aggressive therapy may alter the natural history of this self-perpetuating illness...
  9. doi request reprint Combination immunosuppressant therapy for patients with chronic refractory immune thrombocytopenic purpura
    Donald M Arnold
    Department of Medicine, Michael G DeGroote School of Medicine, McMaster University, Hamilton, ON, Canada
    Blood 115:29-31. 2010
    ..Severe adverse events did not occur. Combination immunosuppressant therapy can produce a rise in the platelet count that is sometimes sustained in refractory ITP patients...
  10. pmc Anti-platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin
    Theodore E Warkentin
    Department of Pathology and Molecular Medicine, McMaster University, Hamilton, ON, Canada
    Blood 106:3791-6. 2005
    ..We conclude that despite similar immunogenicity of fondaparinux and LMWH, PF4/fondaparinux, but not PF4/LMWH, is recognized poorly by the antibodies generated, suggesting that the risk of HIT with fondaparinux likely is very low...
  11. ncbi request reprint An improved definition of immune heparin-induced thrombocytopenia in postoperative orthopedic patients
    Theodore E Warkentin
    McMaster University, The Henderson Research Centre, and the Hamilton Regional Laboratory Medicine Program, Hamilton, Ontario, Canada
    Arch Intern Med 163:2518-24. 2003
    ..We sought to determine an improved definition of thrombocytopenia indicating HIT in postoperative orthopedic patients, including its impact on frequency and thrombotic risk of HIT...
  12. ncbi request reprint Heparin-induced skin lesions and other unusual sequelae of the heparin-induced thrombocytopenia syndrome: a nested cohort study
    Theodore E Warkentin
    Department of Pathology and Molecular Medicine, McMaster University, Hamilton, ON, Canada
    Chest 127:1857-61. 2005
    ....
  13. doi request reprint Prevalence and risk of preexisting heparin-induced thrombocytopenia antibodies in patients with acute VTE
    Theodore E Warkentin
    Faculty of Health Sciences, McMaster University, Hamilton, ON, Canada
    Chest 140:366-73. 2011
    ..Antibody prevalence and patient consequences upon exposure to heparin, low-molecular-weight heparin, and fondaparinux are uncertain...
  14. ncbi request reprint Laboratory testing for the antibodies that cause heparin-induced thrombocytopenia: how much class do we need?
    Theodore E Warkentin
    Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario, Canada Department of Medicine, McMaster University, Hamilton, Ontario, Canada
    J Lab Clin Med 146:341-6. 2005
    ..We conclude that an EIA that detects anti-PF4/polyanion antibodies of only the IgG class has greater diagnostic usefulness in revealing clinical HIT than does an assay that also detects IgA and IgM class antibodies...
  15. doi request reprint Misleading hepatitis B test results due to intravenous immunoglobulin administration: implications for a clinical trial of rituximab in immune thrombocytopenia
    Donald M Arnold
    Department of Medicine, Michael deGroote School of Medicine, McMaster University, Hamilton, Ontario, Canada
    Transfusion 50:2577-81. 2010
    ..A high seroprevalence of anti-HBc observed among patients screened for the trial prompted this substudy to investigate for an association between anti-HBc seropositivity and exposure to intravenous immunoglobulin (IVIG)...
  16. doi request reprint A spontaneous prothrombotic disorder resembling heparin-induced thrombocytopenia
    Theodore E Warkentin
    Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario, Canada
    Am J Med 121:632-6. 2008
    ..We describe a novel syndrome, spontaneous heparin-induced thrombocytopenia, in which clinical and serologic features characteristic of this adverse drug reaction develop in patients despite the absence of preceding heparin therapy...
  17. ncbi request reprint Treatment of heparin-induced thrombocytopenia: a critical review
    Jack Hirsh
    Henderson Research Centre, Henderson Hospital, and the Department of Medicine, McMaster University, Hamilton, Ontario
    Arch Intern Med 164:361-9. 2004
    ....
  18. ncbi request reprint New treatments for idiopathic thrombocytopenic purpura: rethinking old hypotheses
    Donald M Arnold
    Michael G DeGroote School of Medicine, Medicine and Pathology and Molecular Medicine, McMaster University, 1200 Main Street W, Hamilton, Ontario, Canada
    Expert Opin Investig Drugs 18:805-19. 2009
    ..New strategies to reduce platelet destruction, like rituximab, are also effective...
  19. ncbi request reprint Novel treatments for immune thrombocytopenia
    Andrew Shih
    McMaster University, Department of Medicine, Hamilton, Ontario, Canada
    Presse Med 43:e87-95. 2014
    ..An individualized treatment strategy is needed for patients since ITP is a distinctly heterogeneous disease. ..
  20. doi request reprint Rituximab maintenance for relapsed refractory thrombotic thrombocytopenic purpura
    Vinai C Bhagirath
    Department of Medicine, McMaster University, Ontario, Canada
    Transfusion 52:2517-23. 2012
    ....
  21. pmc Platelet count response to H. pylori treatment in patients with immune thrombocytopenic purpura with and without H. pylori infection: a systematic review
    Donald M Arnold
    1Michael G DeGroote School of Medicine, Department of Medicine, McMaster University, Hamilton, Ontario, Canada
    Haematologica 94:850-6. 2009
    ..pylori infection and immune thrombocytopenia in some patients. Randomized trials are needed to determine the applicability of H. pylori eradication therapy across diverse geographical regions...
  22. ncbi request reprint Idiopathic thrombocytopenic purpura complicating pregnancy
    John G Kelton
    Department of Medicine, McMaster University Medical Center, Hamilton, Ontario, Canada
    Blood Rev 16:43-6. 2002
    ..The overall frequency of thrombocytopenia in the infant is quite low, and about 5% of infants will have a birth platelet count less than 20 x 10(9)/L and about 1% will have significant bleeding complications...
  23. ncbi request reprint Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura
    Donald M Arnold
    McMaster University and Juravinski Cancer Centre, Hamilton, Ontario, Canada
    Ann Intern Med 146:25-33. 2007
    ..Rituximab, a monoclonal anti-CD20 antibody, is increasingly used to treat idiopathic thrombocytopenic purpura (ITP)...
  24. ncbi request reprint Dissociation between the level of von Willebrand factor-cleaving protease activity and disease in a patient with congenital thrombotic thrombocytopenic purpura
    Carolyn E Snider
    Department of Medicine, Faculty of Health Sciences, McMaster University, Hamilton, Ontario, Canada
    Am J Hematol 77:387-90. 2004
    ..In addition, it is possible that splenectomy could be an effective treatment option for some patients with severe, congenital TTP...
  25. ncbi request reprint Analyses of cellular multimerin 1 receptors: in vitro evidence of binding mediated by alphaIIbbeta3 and alphavbeta3
    Frédérick Adam
    Departments of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario, Canada
    Thromb Haemost 94:1004-11. 2005
    ..These studies implicate integrin-mediated binding in MMRN1 attachment to cells and indicate that MMRN1 is a ligand for alphaIIbbeta3 and alphavbeta3...
  26. pmc A blinded study of bone marrow examinations in patients with primary immune thrombocytopenia
    Vishwanath K Mahabir
    Department of Medicine, Michael G DeGroote School of Medicine, McMaster University, Hamilton, ON, Canada
    Eur J Haematol 90:121-6. 2013
    ..The objectives of this study were to determine the inter-rater reliability of bone marrow examinations and to identify distinguishing morphological features of ITP bone marrows under controlled conditions...
  27. doi request reprint Diagnosis and management of neonatal alloimmune thrombocytopenia
    Donald M Arnold
    The McMaster Platelet Immunology Diagnostic Laboratory, McMaster University, Hamilton, Ontario, Canada
    Transfus Med Rev 22:255-67. 2008
    ..Improvements in our understanding of the pathophysiology of NAT, and of clinical and laboratory predictors of severity, may help develop better treatments and improve our ability to identify mothers at risk...
  28. ncbi request reprint The IgG subclasses of platelet-associated autoantibodies directed against platelet glycoproteins IIb/IIIa in patients with idiopathic thrombocytopenic purpura
    Howard Chan
    Department of Medicine, McMaster University, Hamilton, Ontario, Canada
    Br J Haematol 122:818-24. 2003
    ..Our results are consistent with the hypothesis that ITP is a heterogeneous disorder and that some patients have evidence of oligoclonality, whereas other patients have polyclonal autoantibodies...
  29. doi request reprint Nonheparin anticoagulants for heparin-induced thrombocytopenia
    John G Kelton
    From the Department of Medicine, Michael G DeGroote School of Medicine, McMaster University J G K, D M A, S M B Canadian Blood Services D M A and the Thrombosis and Atherosclerosis Research Institute S M B all in Hamilton, ON, Canada
    N Engl J Med 368:737-44. 2013
    ..Several agents are in clinical use for this condition, including parenteral direct thrombin inhibitors and parenteral factor Xa inhibitors...
  30. ncbi request reprint A retrospective 11-year analysis of obstetric patients with idiopathic thrombocytopenic purpura
    Kathryn E Webert
    Department of Medicine, McMaster University, Rm HSC 3N43, 1200 Main St W, Hamilton, ON, Canada L8N 3Z5
    Blood 102:4306-11. 2003
    ..6%) required treatment for hemostatic impairment. Two fetal deaths occurred. One was caused by hemorrhage. ITP in pregnancy carries a low risk, but mothers and infants may require therapy to raise their platelet counts...
  31. ncbi request reprint A review of randomized controlled trials using therapeutic apheresis
    Nadine Shehata
    Division of Hematology, Department of Medicine, McMaster University, Hamilton, Ontario, Canada
    Transfus Med Rev 16:200-29. 2002
    ..The effectiveness of apheresis needs to be clarified for several other diseases. As better-designed, randomized trials are performed, the role of apheresis for these indications will be further elucidated...
  32. ncbi request reprint Inhibition of microsurgical thrombosis by the platelet glycoprotein IIb/IIIa antagonist SR121566A
    Shim Ching
    Division of Plastic Surgery, Department of Surgery, St Joseph s Healthcare, Hamilton, Ontario, Canada
    Plast Reconstr Surg 112:177-85. 2003
    ..Glycoprotein IIb/IIIa antagonists represent a new class of anti-platelet agents that may be suited for inhibiting microsurgical thrombosis. This study supports further investigation into the use of these agents in microsurgery...
  33. ncbi request reprint Congenital thrombophilic states associated with venous thrombosis: a qualitative overview and proposed classification system
    Mark A Crowther
    St Joseph s Hospital and McMaster University Medical Centre, Room L208, 50 Charlton Avenue East, Hamilton, Ontario L8N 4A6, Canada
    Ann Intern Med 138:128-34. 2003
    ..The first group is less common than the second, but it is associated with a much higher risk for venous thrombosis. This review provides clinicians with an evidence-based, practical guide to the congenital prothrombotic states...
  34. ncbi request reprint Argatroban anticoagulation in patients with a history of heparin-induced thrombocytopenia
    William H Matthai
    University of Pennsylvania Medical School, 39th and Market Sts WS 392, Philadelphia, PA 10104, USA
    Thromb Res 116:121-6. 2005
    ..We evaluated the safety and efficacy of argatroban, a direct thrombin inhibitor, as an anticoagulant in patients with a history of HIT needing acute anticoagulation...
  35. ncbi request reprint Frequency of heparin-induced thrombocytopenia in critical care patients
    Arun K Verma
    Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, Canada
    Pharmacotherapy 23:745-53. 2003
    ..The low PPV and high NPV of the heparin-PF4 ELISA suggest that it can be used to exclude HIT as a cause of thrombocytopenia in this patient population...
  36. ncbi request reprint Effect of fondaparinux on platelet activation in the presence of heparin-dependent antibodies: a blinded comparative multicenter study with unfractionated heparin
    Pierre Savi
    Cardiovascular Thrombosis Research Department, Sanofi Synthelabo Recherche, Toulouse, France
    Blood 105:139-44. 2005
    ..Together, these results suggest that fondaparinux is nonreactive to HIT sera and raise the possibility that the drug may be used for prophylaxis and treatment of thrombosis in patients with a history of HIT...
  37. ncbi request reprint Argatroban anticoagulation in patients with heparin-induced thrombocytopenia
    Bruce E Lewis
    Department of Cardiology, Loyola University Medical Center, Maywood, Ill, USA
    Arch Intern Med 163:1849-56. 2003
    ..We describe our experience with argatroban, a direct thrombin inhibitor, in patients with HIT or HIT with thrombosis (HITTS)...
  38. ncbi request reprint Heparin-induced thrombocytopenia: an iceberg rising
    Donald M Arnold
    Mayo Clin Proc 80:988-90. 2005
  39. ncbi request reprint IGIV-C, a novel intravenous immunoglobulin: evaluation of safety, efficacy, mechanisms of action, and impact on quality of life
    James B Bussel
    New York Presbyterian Hospital, Payson 695, 525 East 68th Street, New York, New York 10021 4885, USA
    Thromb Haemost 91:771-8. 2004
    ..Viral safety monitoring for HIV, HCV, HBV and Parvovirus B19 showed no seroconversions on study. In conclusion, IGIV-C is as safe and efficacious as IGIV-S/D in treatment of ITP...